JPMorgan cuts Gerresheimer stock price target amid profit warning

JPMorgan analysts lowered Gerresheimer AG's (GXId) price target to €108 from €122.50, maintaining an Overweight rating after the company's third profit warning in two years triggered a 23% stock drop. The shortfall is attributed to a slowdown in the oral liquids segment due to a milder cough and cold season, with speculation that the Bormioli acquisition may have contributed to the issues. Investors are concerned about Gerresheimer's EBITDA trajectory and potential equity dilution, with the stock currently at a decade low.

Analysis

JPMorgan analysts have revised their price target for Gerresheimer AG (GXId) downwards to €108 from €122.50, although they maintain an Overweight rating on the stock. This revision follows Gerresheimer's third profit warning in the past two years, which management attributed to a slowdown in its oral liquids segment, specifically affecting bottles and closures, due to an unexpectedly mild cough and cold season. Analysts speculate that the recently acquired Bormioli may have contributed to these operational challenges, potentially raising questions about the quality of the due diligence process. The market's reaction was severe, with Gerresheimer's shares plummeting 23% on the day of the profit warning, pushing the stock to a decade low and reflecting significant investor frustration. Despite a €1 billion increase in revenues over the past decade, current concerns center on the company's EBITDA trajectory and the risk of potential equity dilution. Gerresheimer plans to issue new mid-term guidance alongside its Q2 results on July 10, followed by a Capital Markets Day later in the summer, which will be critical for addressing these concerns and potentially stabilizing investor confidence, with some market participants hoping for third-party intervention to stabilize the situation.

Key Decisions for Investors

• Investors should closely monitor Gerresheimer's upcoming Q2 results on July 10 and the subsequent Capital Markets Day for new mid-term guidance and clarity on recovery strategies, given the stock's decade-low valuation following its third profit warning and a 23% share price decline.
• Extreme caution is warranted due to repeated earnings disappointments, ongoing concerns regarding EBITDA trajectory, potential equity dilution, and questions surrounding the integration and performance of the Bormioli acquisition, despite JPMorgan's maintained Overweight rating.
• Given the current deeply negative sentiment and significant stock underperformance, investors might consider awaiting tangible evidence of operational turnaround and strategic clarity from management before committing new capital or significantly altering existing positions.